Diffuse large cell lymphoma

Current Opinion in Oncology

Volumn 13, Issue 5, 2001, Pages 325-334

  Coiffier, Bertrand ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CLASSIFICATION; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL FEATURE; GENE EXPRESSION; GENETIC PREDISPOSITION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARGE CELL LYMPHOMA; MALIGNANT TRANSFORMATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; MIDDLE AGED; PROGNOSIS; RECURRENCE; SALVAGE THERAPY;

EID: 0034873899     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200109000-00003     Document Type: Review

References (88)

1. A Revised European-American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
2. Cancer surveillance series: Non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995
3. Non-Hodgkin's lymphoma: An analysis of the Metropolitan Detroit SEER database
4. Pesticide exposures in children with non-Hodgkin lymphoma
5. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997
6. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas
7. A reassessment of primary thyroid lymphoma: High-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma
8. De Novo CD5+ diffuse large B-cell lymphomas: A heterogeneous group containing an unusual form of splenic lymphoma
9. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
10. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene
11. Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons
12. A clinical trial of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
13. Clinicopathologic reassessment of primary cutaneous B-cell lymphomas with immunophenotypic and molecular genetic characterization
14. A predictive model for aggressive non-Hodgkin's lymphoma
15. Prognostic models for diffuse large B-cell lymphoma
16. Prognostic significance of survivin expression in diffuse large B-cell lymphomas
17. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients
18. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma
19. Concurrent disruption of p16(INK4a) and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma
20. Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft
21. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
22. Superiority of the ACVBP regimen over a combined treatment with three cycles of CHOP followed by involved field radiotherapy in patients with low risk localized aggressive non Hodgkin's lymphoma: Results of the LNH93-1 study, ASH meeting
23. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: A survey of the Japan Lymphoma Radiation Therapy Group
24. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
25. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 Protocol. A groupe d'etude des lymphomes de l'adulte study
26. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the jury
27. Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: Lessons learned and challenges remaining
28. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission
29. A randomised British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma
30. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: The LNH87-1 study
31. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group
32. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma
33. Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas
34. Different age limits for erderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age: Analysis of a population-based non-Hodgkin lymphoma registry
35. A comparison of elderly patients with aggressive histology lymphoma who were entered or not entered on to a randomized phase II trial
36. Granulocyte-colony stimulating factot (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy
37. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: Significance and management
38. LNH-84: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma
39. Residual mass in aggressive lymphoma: Does size, measured by computed tomography, influence clinical outcome?
40. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy
41. Aggressive non-Hodgkin lymphoma: Early prediction of outcome with Ga-67 scintigraphy
42. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose
43. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas
44. Persistent tumor F-18-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma
45. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure?
46. High-dose chemoradiotheraphy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: An intention-to-treat analysis
47. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma
48. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: One-half of patients significantly mobilize malignant cells
49. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma
50. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma
51. Allogeneic bone marrow transplantation for lymphoma
52. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): Results of a provincial strategy
53. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma
54. Primary CNS lymphoma: Clinical presentation, pathologic classification, molecular pathogenesis and treatment
55. Therapeutic management of primary central nervous system lymphoma: Lessons from prospective trials
56. Primary intracerebral malignant lymphoma: Report of 248 cases
57. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement: A single center analysis
58. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients
59. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: Significance of very high serum LDH concentrations
60. Primary lymphoma of peripheral nerve: Report of four cases
61. The role of surgery in the treatment of gastrointestinal lymphomas other than low-grade MALT lymphomas
62. Chemotherapy alone versus surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach
63. Primary cutaneous B-cell lymphoma: Review and current concepts
64. Human immunodeficiency virus-associated malignant lymphoma in eastern Denmark diagnosed from 1990 to 1996: Clinical features, histopathology, and association with Epstein-Barr virus and human herpesvirus-8
65. Acquired immunodeficiency syndrome-related lymphoma: Clinical aspects
66. Evolving characteristics of AIDS-related lymphoma
67. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy
68. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma
69. Diagnosis and treatment of transplant-related lymphoma
70. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center
71. Epstein-Barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant
72. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
73. Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma
74. Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell non-Hodgkin's lymphoma
75. BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration
76. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas
77. Nonimmunoglobulin (non-Ig)/BCL6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6
78. Activity of interferon-alpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma
79. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH
80. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas
81. Radioimmunotherapy with iodine 1-131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
82. ASHAP: An effective salvage therapy for recurrent and refractory malignant lymphomas
83. A prospective study of the LMB regimen for diffuse large cell non Hodgkin's lymphoma in adults
84. Gemcitabine for relapsed or resistant lymphoma
85. Etoposide, mitoxantrone and prednisone, a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma
86. VEDex (vincristine, epirubicin dexamethasone): An effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma
87. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyctophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255
88. Combination chemotherapy with irinotecan and Adriamycin for refractory and relapsed non-Hodgkin's lymphoma